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Background—Viruses detected in patients with acute respiratory infections may be the cause of 
illness or asymptomatic shedding.
Objective—To estimate the attributable fraction (AF) and the detection rate attributable to illness 
for each of the different respiratory viruses
Study design—We compared the prevalence of 10 common respiratory viruses (influenza A and 
B viruses, parainfluenza virus 1–3; respiratory syncytial virus (RSV); adenovirus, rhinovirus, 
human metapneumovirus (hMPV) and enterovirus) in both HIV positive and negative patients 
hospitalized with severe acute respiratory illness (SARI), outpatients with influenza-like illness 
(ILI), and control subjects who did not report any febrile, respiratory or gastrointestinal illness 
during 2012–2015 in South Africa.
Results—We enrolled 1959 SARI, 3784 ILI and 1793 controls with a HIV sero-prevalence of 
26%, 30% and 43%, respectively. Influenza virus (AF: 86.3%; 95%CI: 77.7–91.6%), hMPV (AF: 
85.6%; 95%CI: 72.0–92.6%), and RSV (AF: 83.7%; 95%CI: 77.5–88.2%) infections were 
associated with severe disease., while rhinovirus (AF: 46.9%; 95%CI: 37.6–56.5%) and 
adenovirus (AF: 36.4%; 95%CI: 20.6–49.0%) were only moderately associated.
Conclusions—Influenza, RSV and hMPV can be considered pathogens if detected in ILI and 
SARI while rhinovirus and adenovirus were commonly identified in controls suggesting that they 
may cause only a proportion of clinical disease observed in positive patients. Nonetheless, they 
may be important contributors to disease.
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illness; Controls; Pneumonia; HIV; South Africa
1. Background
Pneumonia is a leading cause of childhood mortality globally, with about 1.6 million new 
cases per year, of which 1.2 million occur in the developing world [1] and approximately 
10% are severe enough to require hospitalization [1]. Before the worldwide availability of 
vaccines, Streptococcus pneumoniae (pneumococcus) and Haemophilus influenzae type b 
were identified as the main bacterial causes of pneumonia [1,2]. Now, viruses are more 
commonly detected in patients with acute respiratory infections including pneumonia 
[1,3,4].
Respiratory viruses infections have been detected by polymerase chain reaction (PCR) 
among patients hospitalized with lower respiratory tract infection (LTRI) in several studies 
[5–13]. While the use of sensitive PCR methods has significantly expanded the ability of 
laboratories to detect and identify pathogens, the clinical association between pathogen 
detection and disease remains difficult to interpret when considering viral shedding, 
replication and persistence of nucleic acids present during the pre- or post-syndromic phase 
of infection in the absence of comparison groups [3,4,6,11,12,14]. Without comparing to 
control groups, the clinical relevance of identifying some respiratory pathogens by PCR 
testing remains difficult to determine [3,4,11,12,14–18].
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Understanding the contribution of respiratory viruses to illness would allow the prioritization 
of respiratory pathogens for inclusion in diagnostic tests, disease surveillance, vaccine 
development and treatment.
2. Objectives
To the attributable fraction of 10 common respiratory viruses among patients hospitalized 
with severe acute respiratory illness (SARI) and outpatients with influenza-like illness (ILI) 
compared to control subjects.
3. Study design
3.1. Study design and population
SARI surveillance—Study samples were obtained from participants enrolled in a 
prospective hospital-based surveillance program for SARI initiated in February 2009. The 
methodology and case definition of this study has been previously described [8,19]. For this 
study participants were enrolled at 3 public hospitals in 2 provinces of South Africa 
(Edendale Hospital, KwaZulu-Natal Province; and Klerksdorp and Tshepong Hospitals, 
North West Province) from May 2012 through April 2015.
ILI and control surveillance—Study samples were obtained from participants enrolled 
in an active surveillance program for ILI and controls initiated in May 2012 and running 
through April 2015. The methodology and case definitions of this study have been as 
previously described [14]. Patients presenting with ILI and controls were enrolled at two 
outpatient clinics in the same catchment area to the above mentioned hospitals: Edendale 
Gateway Clinic, KwaZulu-Natal Province, and Jouberton Clinic, North West Province. An 
ILI case was defined as an outpatient of any age presenting with either temperature >38 °C 
or history of fever, and cough of duration of ≤7 days.
A control was defined as an individual presenting at the same outpatient clinic with no 
history of fever, respiratory or gastrointestinal symptoms during the 14 days preceding the 
visit. We aimed to enroll one HIV-infected and one HIV-uninfected control every week in 
each clinic within each of the following age categories: 0–1, 2–4, 5–14, 15–54 and ≥55 
years.
3.2. Respiratory virus detection
Nasopharyngeal aspirates for children <5 years of age and nasopharyngeal and 
oropharyngeal swabs from individuals ≥5 years of age were collected from all enrolled 
patients (SARI, ILI and Controls), placed in viral transport medium, stored at 4–8 °C. All 
specimens were tested for the presence of 10 respiratory viruses (influenza A and B viruses, 
parainfluenza virus (PIV) types 1–3, respiratory syncytial virus (RSV), adenovirus; 
rhinovirus; human metapneumovirus (hMPV), and enterovirus) using a real-time reverse 
transcriptase polymerase chain reaction (rRT-PCR) assay [8]. Among consenting study 
patients, HIV status was established by enzyme-linked immunosorbent assay (ELISA) or 
PCR assay depending on the patients’ age [19].
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3.3. Statistical analysis
We implemented a multivariable multinomial regression model to determine the association 
between specific respiratory viruses among patients with SARI or ILI compared to controls 
enrolled from May 2012 through April 2015. Multinomial regression allows modeling of 
outcome variables with more than 2 categories and relates the probability of being in 
category j to the probability of being in a baseline or reference category. A complete set of 
coefficients are estimated for each of the j levels (patients with ILI or SARI in this analysis) 
that are compared with the baseline category (controls for this analysis) and the effect of 
each predictor in the model is measured as relative risk ratio (RRR). The association of the 
10 viruses with mild (ILI) or severe (SARI) illness was assessed simultaneously using a 
multivariable model to adjust for the potential effect of co-infections. In addition, all 
estimates were adjusted for age (<1, 1–4, 5–24, 25–44, 45–64 and ≥65 years of age), HIV 
serostatus and underlying medical conditions other than HIV.
In addition, we implemented an age-stratified analysis among individuals aged <5 and ≥5 
years of age to evaluate potential differences in disease association in young children and 
older individuals. For both analyses we also adjusted the effect of the viral covariates by age 
within each age strata (<1 and 1–4 years of age for children aged <5 years and 5–24, 25–44, 
45–64 and ≥65 years of age for persons aged ≥5 years), HIV serostatus and underlying 
medical conditions other than HIV.
Subsequently we estimated the attributable fraction (AF) from the relative risk (RR) 
obtained from the multinomial model for each virus using the following formula: AF = (RR 
− 1)/RR×100. Lastly, we adjusted the observed detection rate (PrevObs = n/N) for each virus 
among ILI or SARI cases by the corresponding AF to obtain the prevalence of each virus 
attributable to mild (ILI) or severe (SARI) illness (adjusted prevalence, PrevIllness) using the 
following formula: PrevIllness = PrevObs×AF/100. The analysis was performed using STATA 
13.1 (StataCorp®, Texas, USA).
4. Results
4.1. Characteristics of the study population and detection of respiratory viruses
Over the study period, we enrolled 1959 SARI cases, 3784 ILI cases and 1793 controls. 
Children <5 years of age accounted for 73% (1431/1953); 28% (1075/3783) and 37% 
(658/1135) of SARI cases, ILI cases and controls, respectively. The HIV serostatus was 
known for 79% (1550/1959) of SARI cases, 87% (3280/3784) of ILI cases, and 92% 
(1643/1793) of controls. Among individuals with known HIV serostatus, the HIV prevalence 
was 26% (410/1550) among SARI cases, 30% (974/3280) among ILI cases, and 43% 
(702/1643; reflecting the enrolment criteria) among controls. Among SARI and ILI cases the 
HIV prevalence was lowest among infants <1 year of age [SARI: 10% (75/740), ILI: 2% 
(3/304)] and highest among individuals 25–44 years of age [SARI: 89% (174/196), ILI: 59% 
(608/1035)].
A virus was identified in 70% (1381/1959) of SARI cases, 59% (2230/3784) of ILI cases 
and 36% (645/1793) of controls. Among SARI cases the most commonly detected viruses 
were rhinovirus (34%; 667/1959), RSV (20%; 391/1959) and adenovirus (29%; 379/1959). 
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Rhinovirus (28%; 1064/3784), influenza virus (15%; 577/3784) and adenovirus (12%; 
434/3784) predominated among the ILI cases. Rhinovirus (21%; 374/1793) and adenovirus 
(12%; 207/1793) were the most prevalent among controls (Table 1).
4.2. Attributable fraction of respiratory virus infection to mild or severe illness
In the main unstratified analysis using multivariable multinomial regression, all viruses 
except adenovirus where significantly associated with mild illness (ILI) and all viruses 
except PIV2 were associated with severe illness (SARI) (Tables 1 and 4). Nonetheless, the 
level of association (i.e., magnitude of the AF) varied across pathogens. Among ILI cases 
the AF was highest for influenza (adjusted AF [aAF]: 93.3%; 95% confidence intervals 
[95%CI]: 89.6–95.7%), PIV2 (aAF: 90.8%; 95%CI: 60.5–97.9%) and hMPV (aAF: 86.6%; 
95%CI: 74.9–92.9%) (Table 4). Among SARI cases the AF was highest for influenza (aAF: 
86.3%; 95%CI: 77.7–91.6%), hMPV (aAF: 85.6%; 95%CI: 72.0–92.6%), and RSV (aAF: 
83.7%; 95%CI: 77.5–88.2%) (Table 4).
In the age stratified analysis among children <5 years of age all viruses except adenovirus 
and enterovirus where significantly associated with mild illness (ILI) and all viruses except 
PIV2 were associated with severe illness (SARI) (Tables 2 and 4). Among SARI cases <5 
years of age, the highest significant AF (≥90%) were observed for influenza, hMPV and 
RSV, while the lowest significant AF was observed for enterovirus (38.2%) (Table 4). In this 
group among viruses with significant AF the estimated detection rate attributable to illness 
(adjusted prevalence) was 22.4% for RSV, 18.1% for rhinovirus, 10.1% for adenovirus, 5.2% 
for hMPV, 4.7% for influenza, 2.9% for PIV3, 2.8% for enterovirus and 2.4% for PIV1 
(Table 4).
Among individuals ≥5 years of age adenovirus, RSV and PIV1 were not significantly 
associated with mild illness (ILI) and adenovirus, PIV1-3 and hMPV were not significantly 
associated with severe illness (SARI) (Tables 3 and 4). Among SARI cases ≥5 years of age 
the highest significant AF (>80%) were observed for enterovirus and influenza, while the 
lowest significant AF was observed for rhinovirus (42.7%). In this group among viruses with 
significant AF the estimated detection rate attributable to illness was 8.1% for rhinovirus, 
5.9% for influenza, 3.4% for RSV, and 2.2% for enterovirus (Table 4).
Among ILI cases influenza had the highest AF and estimated prevalence associated with 
illness among children <5 years (AF: 95.8%; PrevIllness: 13.9%) as well as individuals ≥5 
years (AF: 91.9%; PrevIllness: 14.5%) (Table 4).
5. Discussion
We assessed the association between virus detection and mild or severe illness relative to 
controls. The estimated detection rate attributable to illness reported in this study reflects a 
more accurate description of the prevalence of viruses causing respiratory disease in both 
children and adults in South Africa than reporting viral detection rates alone. Most of the 
viral pathogens evaluated in this study were found to be associated with mild or severe 
disease irrespective of HIV status. Nonetheless, the magnitude of this association varied 
between pathogens. Our study suggest that influenza, RSV and hMPV infections are highly 
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associated with severe respiratory illness in South Africa relative to controls, especially in 
children <5 years of age, which mirror the findings of Self et al. [12]. While rhinovirus and 
adenovirus had the lowest estimated AF the estimated detection rate attributable to illness 
remained high indicating that, while these viruses could act both as pathogen and bystander, 
they could also be responsible for a substantial proportion of severe disease. RSV, 
rhinovirus, adenovirus, hMPV and influenza were the most common pathogens causing 
disease among SARI cases, especially in children <5 years of age.
Our findings differ from similar studies which used multiplex PCR to detect a viral aetiology 
in non-invasive respiratory specimens relative to a control group, where fewer viruses were 
associated with disease. A study conducted among children ≤12 years of age hospitalized 
with pneumonia in the Kilifi District hospital in Kenya [6] reported that only RSV 
(identified in 34% of cases) was associated with disease as well as a case-control study 
conducted among children ≤59 months in rural Kenya [11]. Conversely, another study 
conducted in children reported that RSV and influenza were more commonly found among 
cases than controls [20]. In adults RSV, influenza, and hMPV have been shown to be 
associated with disease [21]. It should be noted that these studies had a limited number of 
controls potentially resulting in a lack of power to detect significant disease association for 
pathogens with low detection rates.
In our study RSV was found to be significantly associated with severe respiratory disease 
relative to controls. RSV has been well documented as the leading cause of viral pneumonia 
in children <5 years of age [1,22], but is also increasingly recognized as a cause of severe 
disease in adults [23–27]. Several studies have shown that RSV infection is an important 
cause of illness in the elderly (≥65 years) and high-risk adults, with a disease burden similar 
to that of non-pandemic seasonal influenza [26,28]. Although we found that RSV was 
associated with disease among both children and adults, modeling studies conducted in 
South Africa have not found excess mortality or hospitalizations associated with RSV 
among adults [29,30]. This apparent contradiction may relate to the fact that the burden of 
RSV among older adults in South Africa may be too low to be detected in modeling studies.
While rhinovirus has been shown to be less associated with illness (low attributable fraction) 
in both children and adults, the estimated detection rate attributable to illness remained 
elevated when compared to other pathogens, suggesting that rhinovirus may still causes a 
substantial proportion of clinical disease that manifests either as ILI or SARI. The high 
prevalence of rhinovirus among controls indicates that rhinovirus may potentially have an 
extended shedding period and can be detected in patients without symptoms. Several studies 
have reported the high positivity rate of rhinovirus in asymptomatic individuals and none so 
far have been able to give a clear indication of rhinovirus’ role in severe respiratory 
infection, although several have suggested that rhinovirus can act as both a bystander and a 
pathogen [12,31–34]. Similar results were obtained for adenovirus in this study [18].
In our study, influenza and hMPV were found to be significantly associated with severe 
disease among children less than 5 years of age. Influenza has been described as one of the 
leading causes of pneumonia in children, the elderly, and adults with HIV infection 
[1,19,35,36]. Since 2001, hMPV has been reported worldwide. However, so far studies of 
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hMPV have been limited; although it has been suggested that hMPV mirrors the 
epidemiology of RSV and influenza with more severe infections occurring in the very 
young, elderly and immune-compromised individuals [37,38].
Our study has limitations that warrant discussion. First, several viruses were detected at low 
prevalence in the control group which would account not only for the high adjusted relative 
risk ratios but also for the wide confidence intervals. Second, comparing detection rate of 
pathogens among symptomatic patients with controls does not prove or disprove disease 
association in individual patients. Other approaches such as viral load and host interactions 
are needed to determine what role some of these viruses play in severe respiratory disease, 
while taking into account factors such as replication or persistence of nucleic acids present 
during the pre-or post syndromic phase of infection. Third, we did not adjust for the 
potential role of bacterial infections as this information was not available. The role of 
bacterial super-infection on severe illness following a viral infection cannot be excluded. 
Last, whereas on multivariable analysis we adjusted for the HIV serostatus of the individuals 
enrolled in this study, we were not powered to provide estimates of the AF stratified by HIV 
due to the low detection rate of certain pathogens within each stratum.
In conclusion, influenza, RSV and hMPV can be considered likely pathogens if detected in 
South African patients with ILI or SARI; whereas rhinovirus and adenovirus were 
commonly identified also among controls suggesting that they may cause only a proportion 
of clinical disease observed in positive patients. Nonetheless, given their high estimated 
detection rate attributable to illness, they may be important contributors to disease. This data 
together with other matched case-control studies like PERCH (Pneumonia Etiology 
Research for Child Health) [16] will provide useful information on how each pathogen 
impacts disease severity and may assist to better interpret surveillance data, to prioritize 
pathogens to be included in surveillance programs and to guide prevention interventions.
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v
iru
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PV
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